When there are fewer design elements in a design claim or when the individual elements of the design seem commonplace in isolation, it can be easy ...

Expansion of Patent Portfolio: Extending Innovation and Leadership MediPrint has further solidified its intellectual property portfolio with the recent issuance of U.S. Patent No. 12,178,904 by ...

Expansion of Patent Portfolio: Extending Innovation and ... and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their ...

MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial ...

The uncertainty over the UPC’s long-arm jurisdiction is, in part, a reflection of the fact that there is wider range of European countries for which European patents can be registered ... European ...

Your photos deserve to exist as more than mere bits and bytes. Here's how to pick the right photo printer—whether for humble snapshots or big, bold art prints—and our top lab-tested picks. I ...

The patent application covers methods of treating obese patients by administering Namodenoson in an oral formulation. Can-Fite has already multiple approved patents and corresponding applications ...

The patent process can be complex, but SAS supports its employees through technical forums, internal groups, and patent awards to encourage and simplify submissions. Even augmenting standard ...

In support of this determination, the court cited the fact that Campbell controlled the supply of the racks and cans to the customer ... filed counterclaims of patent invalidity and non-infringement.

The patent covers the oral administration of the drug to treat obesity. Credit: Cynthia A Jackson/Shutterstock. Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for ...